ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Entera Bio Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.94+0.26 (+9.70%)
Close on Oct 19, 2026
- Market cap
- $148.33M
- P/E (TTM)
- 11.8
- Dividend yield
- –
Ownership
Who owns Entera Bio's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
8 buys · 0 sales
Net bought $140.88K
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Fred Knoll | 5,881,879 | 15.00% | 13G (passive) amendment | Nov 14, 2024 |
| Opko Health, Inc. | 3,685,226 | 8.10% | 13G (passive) | Mar 16, 2025 |
| Steven A. Cohen | 2,701,560 | 6.80% | 13G (passive) | Jan 3, 2025 |
| Centillion Fund, Inc. | 2,396,953 | 6.70% | 13G (passive) amendment | Jul 19, 2024 |
| Bvf Partners L P/Il | 17,225,121 | 9.99% | 13D (active) | Jul 28, 2026 |
| Chen Yu | 12,254,901 | 7.10% | 13G (passive) | Jul 28, 2026 |
| Vivo Opportunity, LLC | 11,817,401 | 6.90% | 13G (passive) | Jul 28, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Miranda Jayne Toledano | Chief Executive Officer, Director | 847,135 | 0.49% | Aug 7, 2026 |
| Riccardo Paolo Camisasca | Chief Medical Officer | – | – | Aug 21, 2026 |
| Hillel Galitzer | Chief Operating Officer | 163,566 | 0.09% | Aug 7, 2026 |
| Gregory Burshtein | Chief of R&D | 189,033 | 0.11% | Aug 7, 2026 |
| Dana Yaacov-Garbeli | Chief Financial Officer | 258,172 | 0.15% | Aug 7, 2026 |
| Leslie Velka Gautam | Chief Business Officer | – | – | May 20, 2025 |
| Yonatan Malca | Director | 100,231 | 0.06% | Aug 7, 2026 |
| Haya Taitel | Director | 119,269 | 0.07% | Aug 7, 2026 |
| Steven D. Rubin | Director | 34,117 | 0.02% | Aug 7, 2026 |
| Sean Ellis | Director | 208,132 | 0.12% | Aug 7, 2026 |
| Geno J. Germano | Director | 65,014 | 0.04% | Aug 7, 2026 |
| Gerald M. Ostrov | Director | 75,657 | 0.04% | Jan 2, 2026 |
| Gerald M. Lieberman | Director | 344,654 | 0.20% | Jan 2, 2026 |
| Knoll Capital Management, LLC | 10% owner | 5,534,275 | 3.20% | Nov 20, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sean Ellis Director | Aug 7, 2026 | Award | +20,034 | – | – | 208,132 |
| Yonatan Malca Director | Aug 7, 2026 | Award | +22,815 | – | – | 100,231 |
| Steven D. Rubin Director | Aug 7, 2026 | Award | +19,117 | – | – | 34,117 |
| Haya Taitel Director | Aug 7, 2026 | Award | +20,790 | – | – | 119,269 |
| Geno J. Germano Director | Aug 7, 2026 | Award | +25,014 | – | – | 65,014 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Jul 14, 2026 | Award | +72,993 | – | – | 847,135 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Jul 14, 2026 | Award | +347,567 | – | – | 774,142 |
| Dana Yaacov-Garbeli Chief Financial Officer | May 7, 2026 | Award | +58,394 | – | – | 171,441 |
| Gregory Burshtein Chief of R&D | May 7, 2026 | Award | +87,591 | – | – | 189,033 |
| Hillel Galitzer Chief Operating Officer | May 7, 2026 | Award | +72,993 | – | – | 163,566 |
| Geno J. Germano Director | Mar 9, 2026 | Buy | +20,000 | $1.30 | $26.00K | 40,000 |
| Sean Ellis Director | Mar 5, 2026 | Buy | +10,000 | $1.23 | $12.30K | 188,098 |
| Steven D. Rubin Director | Feb 12, 2026 | Buy | +5,000 | $1.49 | $7.45K | 15,000 |
| Geno J. Germano Director | Feb 10, 2026 | Buy | +20,000 | $1.49 | $29.80K | – |
| Haya Taitel Director | Feb 10, 2026 | Buy | +7,500 | $1.48 | $11.10K | – |
| Sean Ellis Director | Feb 9, 2026 | Buy | +18,000 | $1.24 | $22.32K | 178,098 |
| Steven D. Rubin Director | Feb 9, 2026 | Buy | +10,000 | $1.20 | $12.00K | 10,000 |
| Haya Taitel Director | Jan 1, 2026 | Award | +26,329 | – | – | 90,979 |
| Gerald M. Ostrov Director | Jan 1, 2026 | Award | +28,721 | – | – | 75,657 |
| Gerald M. Lieberman Director | Jan 1, 2026 | Award | +38,294 | – | – | 338,454 |
| Yonatan Malca Director | Jan 1, 2026 | Award | +30,157 | – | – | 77,416 |
| Sean Ellis Director | Jan 1, 2026 | Award | +25,371 | – | – | 160,098 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Dec 29, 2025 | Buy | +11,000 | $1.81 | $19.91K | 426,575 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Jul 16, 2025 | Award | +136,842 | – | – | 371,715 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Jul 16, 2025 | Award | +43,860 | – | – | 415,575 |
| Gregory Burshtein Chief of R&D | Jul 16, 2025 | Award | +26,316 | – | – | 101,442 |
| Dana Yaacov-Garbeli Chief Financial Officer | Jul 16, 2025 | Award | +26,316 | – | – | 113,047 |
| Hillel Galitzer Chief Operating Officer | Apr 28, 2025 | Award | +26,316 | – | – | 90,573 |
| Gerald M. Lieberman Director | Apr 1, 2025 | Option exercise | +23,952 | $1.00 | $23.95K | 300,160 |
| Gerald M. Ostrov Director | Jan 15, 2025 | Award | +8,038 | – | – | 46,936 |
| Gerald M. Lieberman Director | Jan 15, 2025 | Award | +10,717 | – | – | 276,208 |
| Yonatan Malca Director | Jan 15, 2025 | Award | +8,216 | – | – | 47,259 |
| Sean Ellis Director | Jan 15, 2025 | Award | +7,100 | – | – | 134,727 |
| Haya Taitel Director | Jan 15, 2025 | Award | +6,922 | – | – | 64,650 |
| Haya Taitel Director | Oct 2, 2024 | Award | +7,278 | – | – | 57,728 |
| Gerald M. Ostrov Director | Oct 2, 2024 | Award | +8,452 | – | – | 38,898 |
| Sean Ellis Director | Oct 2, 2024 | Award | +7,466 | – | – | 127,627 |
| Yonatan Malca Director | Oct 2, 2024 | Award | +8,639 | – | – | 39,043 |
| Gerald M. Lieberman Director | Oct 2, 2024 | Award | +11,269 | – | – | 265,491 |
| Gerald M. Lieberman Director | Aug 27, 2024 | Award | +27,261 | – | – | 254,222 |
| Gerald M. Ostrov Director | Aug 27, 2024 | Award | +20,446 | – | – | 30,446 |
| Haya Taitel Director | Aug 27, 2024 | Award | +15,335 | – | – | 50,450 |
| Sean Ellis Director | Aug 27, 2024 | Award | +18,061 | – | – | 120,161 |
| Yonatan Malca Director | Aug 27, 2024 | Award | +23,172 | – | – | 30,404 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Jul 31, 2024 | Award | +124,121 | – | – | 234,873 |
| Dana Yaacov-Garbeli Chief Financial Officer | Apr 19, 2024 | Award | +30,151 | – | – | 86,731 |
| Hillel Galitzer Chief Operating Officer | Apr 19, 2024 | Award | +30,151 | – | – | 64,257 |
| Dana Yaacov-Garbeli Chief Financial Officer | Apr 19, 2024 | Award | +30,151 | – | – | 86,731 |
| Haya Taitel Director | Jan 12, 2024 | Buy | +9,500 | $0.99 | $9.41K | 35,115 |
| Haya Taitel Director | Jan 10, 2024 | Buy | +7,615 | $0.77 | $5.86K | 25,615 |
| Gerald M. Lieberman Director | Dec 22, 2023 | Buy | +23,952 | $0.71 | $17.01K | 226,961 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Dec 22, 2023 | Buy | +23,952 | $0.71 | $17.01K | 110,752 |
| Haya Taitel Director | Aug 22, 2023 | Buy | +18,000 | $0.62 | $11.16K | 18,000 |
| Gerald M. Lieberman Director | Aug 21, 2023 | Buy | +20,000 | $0.59 | $11.80K | 214,209 |
| Sean Ellis Director | Aug 21, 2023 | Buy | +40,000 | $0.60 | $24.00K | 102,100 |
| Miranda Jayne Toledano Chief Executive Officer, Director | Apr 4, 2023 | Buy | +30,000 | $1.01 | $30.30K | 86,800 |
| Dana Yaacov-Garbeli Chief Financial Officer | Nov 14, 2022 | Buy | +26,580 | $0.54 | $14.35K | 56,580 |
| Gerald M. Lieberman Director | Nov 14, 2022 | Buy | +34,000 | $0.57 | $19.38K | 194,209 |
| Gerald M. Lieberman Director | Nov 14, 2022 | Buy | +4,000 | $0.56 | $2.24K | 6,200 |
| Gerald M. Lieberman Director | Nov 14, 2022 | Buy | +4,000 | $0.56 | $2.24K | 6,200 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.